Doramapimod (Synonyms: BIRB 796)

Name: Doramapimod
Brand: MedChemExpress
SKU: HY-10320
Rating: 5.0 (51 reviews)

Cat. No.: HY-10320 Purity: 99.93%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Doramapimod (BIRB 796) is an orally active, highly potent p38 MAPK inhibitor, which has an IC₅₀ for p38α=38 nM, for p38β=65 nM, for p38γ=200 nM, and for p38δ=520 nM. Doramapimod has picomolar affinity for p38 kinase (K_d=0.1 nM). Doramapimod also inhibits B-Raf with an IC₅₀ of 83 nM.

For research use only. We do not sell to patients.

CAS No. : 285983-48-4

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	Get quote
1 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 51 publication(s) in Google Scholar

Other Forms of Doramapimod:

51 Publications Citing Use of MCE Doramapimod

2D/3D Cell Culture and Differentiation

: Doramapimod purchased from MedChemExpress. Usage Cited in: Engineering. 2025 Mar 4.; BIRB 796 (10 μM, 36 h) inhibited the expression of p-p38 MAPK induced by LPS (200 ng/mL) in THP-1 cells.

: Doramapimod purchased from MedChemExpress. Usage Cited in: Redox Biol. 2024 Sep 6:76:103344. [Abstract]; BIRB 796 (DORA, 10 μM, 4 h) inhibited the expression of p-p38 MAPK induced by LPS (1000 ng/mL) in 10T1/2 cells.

: Doramapimod purchased from MedChemExpress. Usage Cited in: Redox Biol. 2024 Sep 6:76:103344. [Abstract]; BIRB 796 (DORA, 10 μM, 4 h) inhibited the mitochondrial recruitment of DRP1 and the fission induced by LPS (1000 ng/mL) in 10T1/2 cells.

: Doramapimod purchased from MedChemExpress. Usage Cited in: Cell Res. 2020 Jul;30(7):574-589. [Abstract]; Birb 796 (0.1, 0.3, 1, and 3 μM, 3 days) impaired the ability of SSK1 (0.5 μM,3 days) to specifically kill senescent HUVEC.

: Doramapimod purchased from MedChemExpress. Usage Cited in: Nature. 2019 Jul;571(7763):127-131. [Abstract]; BIRB 796 (1 μM, 4.5 h) did not abrogate EGF-induced pUGDH in A549 cells stably expressing Flag–UGDH.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All p38 MAPK Isoform Specific Products:

View All Isoforms

p38 MAPK Akt1 p38α p38β MAPK13 p38δ p38γ

View All Raf Isoform Specific Products:

View All Isoforms

B-Raf C-Raf Raf

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]^[2]

p38α

38 nM (IC₅₀)

p38β

65 nM (IC₅₀)

p38δ

520 nM (IC₅₀)

p38γ

200 nM (IC₅₀)

B-Raf

83.4 nM (IC₅₀)

Abl

14600 nM (IC₅₀)

p38 MAP kinase

0.1 nM (Kd)

Cellular Effect

Cell Line	Type	Value	Description	References
PBMC	IC₅₀	15 nM Compound: BIRB-796	Antiinflammatory activity in LPS-stimulated human isolated PBMC assessed as inhibition of TNFalpha production preincubated for 1 hr prior to LPS-challenge by ELISA Antiinflammatory activity in LPS-stimulated human isolated PBMC assessed as inhibition of TNFalpha production preincubated for 1 hr prior to LPS-challenge by ELISA	[PMID: 21888439]
PBMC	IC₅₀	30 nM Compound: BIRB-796	Inhibition of LPS-stimulated TNFalpha release in human PBMC by ELISA Inhibition of LPS-stimulated TNFalpha release in human PBMC by ELISA	[PMID: 18602262]
THP-1	EC₅₀	18 nM Compound: 45	Inhibition of LPS-induced tumor necrosis factor-alpha (TNF-alpha) production in THP-1 cells Inhibition of LPS-induced tumor necrosis factor-alpha (TNF-alpha) production in THP-1 cells	[PMID: 12086485]
THP-1	IC₅₀	0.013 μM Compound: BIRB-796	Inhibition of LPS-induced TNFalpha production in human THP1 cells Inhibition of LPS-induced TNFalpha production in human THP1 cells	[PMID: 18325768]
THP-1	IC₅₀	18 nM Compound: 1, BIRB-796	Inhibition of LPS-induced TNFalpha production in human THP1 cells Inhibition of LPS-induced TNFalpha production in human THP1 cells	[PMID: 19356929]
THP-1	IC₅₀	18 nM Compound: BIRB-796	Inhibition of LPS-induced TNFalpha production in THP1 cells Inhibition of LPS-induced TNFalpha production in THP1 cells	[PMID: 17560108]
THP-1	IC₅₀	18 nM Compound: BIRB-796	Inhibition of LPS-stimulated TNFalpha production in human THP1 cells Inhibition of LPS-stimulated TNFalpha production in human THP1 cells	[PMID: 18462940]
U-937	IC₅₀	15 nM Compound: 4; BIRB-796	Antiinflammatory activity in differentiated human U937 cells assessed as inhibition of LPS-induced TNFalpha production preincubated for 2 hrs followed by LPS-stimulation for 4 hrs by sandwich ELISA relative to vehicle-treated control Antiinflammatory activity in differentiated human U937 cells assessed as inhibition of LPS-induced TNFalpha production preincubated for 2 hrs followed by LPS-stimulation for 4 hrs by sandwich ELISA relative to vehicle-treated control	[PMID: 26800309]

In Vitro

Doramapimod (BIRB 796) is usually associated with inflammation because of its role in T-cell proliferation and cytokine production^[1].
Doramapimod (BIRB 796) blocks the stress-induced phosphorylation of the scaffold protein SAP97, further establishing that this is a physiological substrate of SAPK3/p38γ. The binding of Doramapimod to the p38 MAPKs or JNK1/2 is impairing their phosphorylation by the upstream kinase MKK6 or MKK4^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The mean xenograft weigh of Doramapimod (BIRB 796) is lighter than control. The inhibition rate of Doramapimod is 1.93%^[4].
The Doramapimod (BIRB 796) treatment slightly reduces blood pressure (166±7 mm Hg at week 7; P<0.05), whereas SD rats are normotensive (123±3 mm Hg). Despite the reduction in blood pressure, untreated and Doramapimod-treated dTGRs have similar heart weight and cardiac hypertrophy indices (heart-to-tibia ratio), which are significantly higher compare with nontransgenic SD rats (310±6 versus 307±6 versus 206±5 mg/cm, respectively; P<0.05)^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

527.66

Formula

C₃₁H₃₇N₅O₃

CAS No.

285983-48-4

Appearance

Solid

Color

Off-white to gray

SMILES

O=C(NC1=CC(C(C)(C)C)=NN1C2=CC=C(C)C=C2)NC3=C4C=CC=CC4=C(OCCN5CCOCC5)C=C3

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (189.52 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 33.33 mg/mL (63.17 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.8952 mL	9.4758 mL	18.9516 mL
5 mM	0.3790 mL	1.8952 mL	3.7903 mL
10 mM	0.1895 mL	0.9476 mL	1.8952 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (4.74 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.94 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (3.94 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.98%

Select Batch:

Data Sheet (285 KB) SDS (396 KB)

COA (255 KB) LCMS (257 KB) Elemental Analysis Report (112 KB)

Handling Instructions (2659 KB)

References

[1]. Dietrich J, et al. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors. Bioorg Med Chem. 2010 Aug 1;18(15):5738-48 [Content Brief]

[2]. Cicenas J, et al. JNK, p38, ERK, and SGK1 Inhibitors in Cancer. Cancers (Basel). 2017 Dec 21;10(1). pii: E1. [Content Brief]

[3]. Kuma Y, et al. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J Biol Chem, 2005, 280(20), 19472-19479. [Content Brief]

[4]. He D, et al. BIRB796, the inhibitor of p38 mitogen-activated protein kinase, enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cells. PLoS One. 2013;8(1):e54181. [Content Brief]

[5]. Park JK, et al. p38 mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced target organ damage. Hypertension. 2007 Mar;49(3):481-9. [Content Brief]

Cell Assay ^[3]	Human embryonic kidney (HEK) 293 and HeLa cells are exposed to 0.5 M sorbitol for 30 min or 100 ng/mL EGF for 10 min and then lysed in buffer A (50 mM Tris-HCl, pH 7.5, 1 mM EGTA, 1 mM EDTA, 1 mM sodium orthovanadate, 10 mM sodium fluoride, 50 mM sodium β-glycerophosphate, 5 mM pyrophosphate, 0.27 M sucrose, 0.1 mM phenylmethylsulfonyl fluoride, 1% (v/v) Triton X-100) plus 0.1% (v/v) 2-mercaptoethanol and Complete proteinase inhibitor mixture. Lysates are centrifuged at 18,000× g for 5 min at 4°C, and the supernatants are removed, quick-frozen in liquid nitrogen, and stored at -20°C until use. When required, cells are preincubated for 1 h without or with 10 μM SB 203580 or 10 μM PD 184352 or with different concentrations of Doramapimod for the times indicated in the figures^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[4]^[5]	Mice^[4] Athymic nude mice (BALB/c-nu/nu), 6 to 8 weeks of age and weighing 18 to 24 g, are used. The mice are treated with Doramapimod (10 mg/kg p.o., every 3 days×5). The body weights of the animals and the two perpendicular tumor diameters (A and B) are recorded every 3 days, and the tumor volume (V) is estimated. Rats^[5] Male transgenic dTGRs (RCC Ltd) and age-matched nontransgenic Sprague-Dawley (SD) rats (MDC) are use. 2 different protocols are performed. In protocol 2, untreated dTGR (n=15), dTGR+BIRB796 (30 mg/kg per day in the diet for 3 weeks; n=11), and SD (n=8 each group) rats are analyzed. Systolic blood pressure is measured weekly by tail cuff. Twenty-four-hour urine samples are collected in metabolic cages from weeks 5 to 7. Serum is collected at week 7. Serum creatinine and cystatin C are measured by clinical routine assays. Urinary rat albumin is determined by enzyme-linked immunosorbent assay. The aim of protocol 2 is to focus on electrophysiological alterations and mortality. Untreated dTGR (n=10), dTGR+BIRB796 (n=10), and SD (n=10) rats are studied up to week 8. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Dietrich J, et al. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors. Bioorg Med Chem. 2010 Aug 1;18(15):5738-48 [Content Brief] [2]. Cicenas J, et al. JNK, p38, ERK, and SGK1 Inhibitors in Cancer. Cancers (Basel). 2017 Dec 21;10(1). pii: E1. [Content Brief] [3]. Kuma Y, et al. BIRB796 inhibits all p38 MAPK isoforms in vitro and in vivo. J Biol Chem, 2005, 280(20), 19472-19479. [Content Brief] [4]. He D, et al. BIRB796, the inhibitor of p38 mitogen-activated protein kinase, enhances the efficacy of chemotherapeutic agents in ABCB1 overexpression cells. PLoS One. 2013;8(1):e54181. [Content Brief] [5]. Park JK, et al. p38 mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced target organ damage. Hypertension. 2007 Mar;49(3):481-9. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

Ethanol / DMSO	1 mM	1.8952 mL	9.4758 mL	18.9516 mL	47.3790 mL
	5 mM	0.3790 mL	1.8952 mL	3.7903 mL	9.4758 mL
	10 mM	0.1895 mL	0.9476 mL	1.8952 mL	4.7379 mL
	15 mM	0.1263 mL	0.6317 mL	1.2634 mL	3.1586 mL
	20 mM	0.0948 mL	0.4738 mL	0.9476 mL	2.3689 mL
	25 mM	0.0758 mL	0.3790 mL	0.7581 mL	1.8952 mL
	30 mM	0.0632 mL	0.3159 mL	0.6317 mL	1.5793 mL
	40 mM	0.0474 mL	0.2369 mL	0.4738 mL	1.1845 mL
	50 mM	0.0379 mL	0.1895 mL	0.3790 mL	0.9476 mL
	60 mM	0.0316 mL	0.1579 mL	0.3159 mL	0.7896 mL
DMSO	80 mM	0.0237 mL	0.1184 mL	0.2369 mL	0.5922 mL
DMSO	100 mM	0.0190 mL	0.0948 mL	0.1895 mL	0.4738 mL

Doramapimod Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Doramapimod285983-48-4BIRB 796BIRB796BIRB-796p38 MAPKRafAutophagyRaf kinasesInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Doramapimod (Synonyms: BIRB 796)

Customer Review

Other Forms of Doramapimod:

Doramapimod Related Antibodies

51 Publications Citing Use of MCE Doramapimod

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All p38 MAPK Isoform Specific Products:

View All Raf Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Doramapimod Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Doramapimod Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report